Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Rev Gastroenterol Peru ; 39(3): 276-279, 2019.
Artigo em Espanhol | MEDLINE | ID: mdl-31688853

RESUMO

Duodenal type follicular lymphoma is a rare malignancy accounting for less than 4% of primary non-Hodgkin lymphomas of the gastrointestinal tract and it is a new entity that was recently described in the new update WHO 2016. Data regarding long-term outcome are currently lacking, and for that reason, a consensus on the management of this disease has not been established and treatment. We report a case of a 57-year-old female patient diagnosed with duodenal- type follicular lymphoma grade 3a who was treated with R-CHOP. The aim of this study is to add more data for a greater characterization of the entity and thus select the best management for each case.


Assuntos
Neoplasias Duodenais , Linfoma Folicular , Neoplasias Duodenais/classificação , Neoplasias Duodenais/tratamento farmacológico , Neoplasias Duodenais/patologia , Feminino , Humanos , Linfoma Folicular/classificação , Linfoma Folicular/tratamento farmacológico , Linfoma Folicular/patologia , Pessoa de Meia-Idade
2.
Leuk Res ; 102: 106513, 2021 03.
Artigo em Inglês | MEDLINE | ID: mdl-33561632

RESUMO

Data on response and survival outcomes of Latin American patients with diffuse Large B- cell lymphoma (DLBCL) are limited. We describe the clinical, inflammatory and immunohistochemical features of a cohort of DLBCL Peruvian patients treated with chemoimmunotherapy between 2010 and 2015. Logistic models were fitted for complete response (CR), and Cox proportional-hazard regression for progression-free survival (PFS) and overall survival (OS). Seventy-three patients were included in this analysis, 41 % had high/high-intermediate IPI and 48 % had high/high-intermediate NCCN-IPI scores, 41 % had non-germinal center (NGC) profile and 36 % were double expressors. CR was attained in 63 % of patients, median PFS was 53 months and median OS was 80 months. Both IPI and NCCN-IPI scores were statistically associated with PFS and OS. Neutrophil/lymphocyte ratio (NLR) ≥4 was associated with lower odds of CR (OR 0.19, p = 0.007), worse PFS (HR 2.67, p = 0.02) and worse OS (HR 2.77, p = 0.02). NLR ≥ 4 remained significant after adjusting for the IPI score and had a trend towards significance when adjusted for the NCCN-IPI score. Albumin <3.5 g/dl was associated with worse OS when adjusted for the NCCN-IPI score (HR 2.96, p = 0.04). NGC profile and double expressors were not prognostic. Our study identified NLR ≥ 4 and albumin <3.5 g/dl as potential adverse factors in DLBCL patients and could add to the prognostic value of the IPI or the NCCN-IPI scores.


Assuntos
Biomarcadores Tumorais/análise , Linfoma Difuso de Grandes Células B/imunologia , Linfoma Difuso de Grandes Células B/patologia , Resultado do Tratamento , Adulto , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica , Estudos de Coortes , Ciclofosfamida , Doxorrubicina , Etoposídeo , Feminino , Humanos , Imuno-Histoquímica , Inflamação/patologia , Linfoma Difuso de Grandes Células B/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Peru , Prednisona , Prognóstico , Intervalo Livre de Progressão , Estudos Retrospectivos , Fatores de Risco , Rituximab , Vincristina
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA